MARKET

KPRX

KPRX

KIORA PHARMACEUTICALS INC
NASDAQ
4.380
-0.120
-2.67%
Opening 11:38 07/22 EDT
OPEN
4.390
PREV CLOSE
4.500
HIGH
4.460
LOW
4.360
VOLUME
2.95K
TURNOVER
0
52 WEEK HIGH
8.98
52 WEEK LOW
3.600
MARKET CAP
13.01M
P/E (TTM)
-0.3046
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at KPRX last week (0715-0719)?
Weekly Report · 5h ago
KIORA PHARMACEUTICALS INC <KPRX.O>: H.C. WAINWRIGHT ADJUSTS TARGET PRICE TO $10 FROM $2 TO REFLECT 1-FOR-9 REVERSE STOCK SPLIT
Reuters · 6h ago
Buy Rating Affirmed for Kiora Pharmaceuticals Amid Strategic Enhancements and Clinical Progress
TipRanks · 6h ago
U.S. RESEARCH ROUNDUP-Casella Waste Systems, Clean Harbors, Crowdstrike
Wall Street analysts revise their ratings and price targets on several U.S.-listed companies. Casella Waste Systems, Clean Harbors, Crowdstrike and United Rentals among those. American Airlines, Amazon.com and Abercrombie & Fitch among companies with new targets.
Reuters · 9h ago
U.S. RESEARCH ROUNDUP-Align Technology, McKesson, Schneider National
Wall Street analysts revise their ratings and price targets on several U.S.-listed companies. Align Technology, McKesson, and Schneider National have lower targets. Abercrombie & Fitch, American Airlines and Amazon.com among the companies with new targets cut.
Reuters · 9h ago
Weekly Report: what happened at KPRX last week (0708-0712)?
Weekly Report · 07/15 11:21
Weekly Report: what happened at KPRX last week (0701-0705)?
Weekly Report · 07/08 11:22
Kiora Pharmaceuticals Announces Board Appointment, Regains Nasdaq Compliance
TipRanks · 07/01 11:34
More
About KPRX
Kiora Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company. The Company is focused on developing and commercializing therapies for the treatment of orphan retinal diseases. Its pipeline consists of three product candidates, including KIO-301, KIO-104, KIO-101 and KIO-201. Its lead product, KIO-301, is a vision-restoring small molecule that is designed to restore vision in patients with inherited and age-related degenerative retinal diseases, including retinitis pigmentosa (RP). KIO-104 is a next generation, non-steroidal, immuno-modulatory, small-molecule inhibitor of Dihydroorotate Dehydrogenase (DHODH), which is being develop for the treatment of Posterior Non-Infectious Uveitis, a rare T cell-mediated, intraocular inflammatory disease. KIO-101 focuses on treating the ocular manifestation of patients with autoimmune diseases, including rheumatoid arthritis, and as such is termed the Ocular Presentation of Rheumatoid Arthritis and Other Autoimmune Diseases (OPRA+).

Webull offers Kiora Pharmaceuticals Inc stock information, including NASDAQ: KPRX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, KPRX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading KPRX stock methods without spending real money on the virtual paper trading platform.